Table 1.

Patient demographics and characteristics of tumors implanted

	T(ID)	Age	Sex	VHL	Source	Histology	Sarc.	Grade	Foc.	Size	pT	pN	TG-0	TG≥2
1	114	69	M	mut	primary	clear-cell	Y	4	uni	10	3	0	Y	N
2	115	65	F	mut	primary	clear-cell	N	4	uni	8	2	x	Y	Y
3	116	66	M	mut	primary	clear-cell	Y	n/a	uni	17	4	0	N	N
4	117	61	M	n/a	primary	papillary	N	3	uni	4	1	x	N	N
5	118	65	F	mut	primary	clear-cell	N	2	uni	2.5	1	x	N	N
6	119	79	F	n/a	primary	clear-cell	N	3	uni	5.7	1	x	N	N
7	120	62	M	n/a	primary	clear-cell	N	1	uni	2.9	1	x	N	N
8	121	78	F	n/a	primary	papillary	N	2	uni	3	1	x	Y	Y
9	122	68	F	n/a	primary	chromophobe	N	3	uni	25	3	0	N	N
10	123	56	M	n/a	primary	papillary	N	3	multi	3.1	1	x	N	N
11	124	63	M	n/a	primary	clear-cell	N	2	uni	3.2	1	x	N	N
12	125	62	F	mut	primary	clear-cell	N	2	uni	4.5	1	x	Y	N
13	126	53	M	mut	primary	clear-cell	N	2	uni	4.5	1	x	N	N
14	127	35	M	mut	primary	clear-cell	N	3	uni	6.2	3	x	Y	Y
15	128	71	M	mut	primary	clear-cell	N	3	uni	4	1	x	N	N
16	129	67	M	n/a	met	clear-cell	N	n/a	n/a	4	n/a	n/a	N	N
17	130	61	F	mut	primary	clear-cell	N	2	uni	6	3	x	N	N
18	131	49	F	mut	primary	clear-cell	N	2	uni	3	1	0	Y	N
19	132	57	M	n/a	primary	papillary	N	3	uni	7.9	2	0	N	N
20	133	58	F	mut	primary	clear-cell	N	2	uni	7.2	3	0	N	N
21	134	59	F	n/a	primary	clear-cell	N	2	uni	1.1	1	x	N	N
22	135	63	M	n/a	primary	clear-cell	N	1	uni	2.9	1	x	N	N
23	136	73	F	wt	primary	clear-cell	N	2	uni	8.5	2	x	N	N
24	137	77	M	n/a	primary	papillary	N	3	uni	2.2	1	x	Y	N
25	138	68	F	n/a	primary	chromophobe	N	2	uni	5.4	1	x	N	N
26	139	66	M	n/a	primary	papillary	N	2	uni	8.5	2	x	Y	N
27	140	52	M	n/a	primary	papillary	N	3	multi	6.2	1	x	N	N
28	141	51	M	n/a	primary	chromophobe	N	3	uni	5.7	1	x	N	N
29	142	56	F	mut	primary	clear-cell	N	3	uni	8.6	3	x	Y	Y
30	143	74	F	wt	primary	clear-cell	Y	4	uni	11	4	x	Y	Y
31	144	71	M	mut	primary	clear-cell	N	4	uni	7.5	2	1	Y	Y*
32	145	55	F	mut	primary	clear-cell	N	2	uni	7	1	x	Y	N
33	146	60	F	mut	primary	clear-cell	N	2	uni	4	1	x	N	N
34	147	59	M	n/a	primary	liposarcoma	n/a	n/a	n/a	14	n/a	n/a	N	N
35	148	64	M	n/a	primary	papillary	N	2	uni	6.5	1	x	N	N
36	149	56	M	wt	primary	clear-cell	Y	4	uni	11.5	3	0	N	N
37	150	50	F	mut	primary	clear-cell	N	3	uni	6.7	3	x	Y	N
38	151	74	M	mut	primary	clear-cell	N	2	uni	7.7	2	x	Y	N
39	152	25	F	n/a	met	papillary	N	n/a	n/a	4.5	n/a	n/a	Y	Y
40	153	62	M	mut	primary	clear-cell	N	2	uni	3.5	1	x	Y	N
41	154	62	M	n/a	primary	oncocytoma	N	n/a	n/a	4	n/a	n/a	N	N
42	155	64	M	mut	primary	clear-cell	Y	4	uni	10	3	0	N	N
43	156	65	F	n/a	primary	papillary	N	3	uni	11.5	2	0	Y	Y
44	157	72	F	mut	primary	clear-cell	N	2	uni	5.2	1	x	N	N
45	158	82	F	mut	primary	clear-cell	Y	3	multi	12.7	3	x	Y	Y
46	159	24	M	n/a	primary	clear-cell	N	2	multi	3	1	x	N	N
47	160	62	M	mut	primary	clear-cell	N	2	uni	4.2	1	x	N	N
48	161	36	M	mut	primary	clear-cell	N	2	uni	8.4	2	x	Y	N
49	162	56	M	mut	primary	clear-cell	N	3	uni	7.2	3	x	Y	N
50	163	52	M	mut	primary	clear-cell	Y	4	uni	4.5	1	0	N	N
51	164	75	M	wt	primary	clear-cell	Y	4	uni	11.3	4	x	Y	Y
52	165	42	M	mut	met	clear-cell	N	3	n/a	1.3	n/a	n/a	Y	Y
53	166	56	M	mut	primary	clear-cell	Y	4	uni	9	3	1	Y	Y*
54	167	74	M	n/a	primary	clear-cell	N	3	uni	4	1	x	N	N
55	168	53	M	n/a	primary	unclassified	Y	4	uni	8	3	1	Y	Y
56	169	52	M	n/a	primary	unclassified	N	4	uni	5.5	4	1	Y	Y
57	170	62	F	mut	primary	clear-cell	N	4	uni	8	3	0	N	N
58	171	62	F	mut	primary	clear-cell	N	2	uni	4.2	1	x	N	N
59	172	61	F	n/a	primary	cystic nephr	N	n/a	n/a	10.7	n/a	n/a	N	N
60	173	50	M	mut	primary	clear-cell	N	3	multi	12	3	x	Y	N
61	174	70	F	n/a	primary	oncocytoma	N	n/a	n/a	3.5	n/a	n/a	N	N
62	175	62	F	mut	primary	clear-cell	N	4	uni	11.5	2	0	N	N
63	176	71	M	n/a	primary	papillary	N	3	uni	11.5	3	1	N	N
64	177	56	F	n/a	primary	clear-cell	N	2	uni	3.2	1	x	Y	N
65	178	51	M	n/a	primary	papillary	N	2	uni	5.5	1	x	Y	N
66	179	60	M	n/a	primary	clear-cell	N	3	uni	7.5	2	x	N	N
67	180	56	M	mut	met	clear-cell	N	n/a	n/a	3.5	n/a	n/a	Y	Y
68	181	71	M	n/a	primary	clear-cell	N	3	uni	12	3	0	N	N
69	182	65	M	n/a	primary	clear-cell	N	3	uni	6	3	1	N	N
70	183	56	M	mut	primary	clear-cell	N	2	uni	4.3	1	x	N	N
71	184	49	M	mut	primary	clear-cell	N	3	uni	10	3	0	N	N
72	185	78	F	n/a	primary	oncocytoma	N	n/a	n/a	6	n/a	n/a	Y	N
73	186	51	M	n/a	primary	papillary	N	3	uni	9	2	x	N	N
74	187	45	M	n/a	primary	unclassified	N	3	multi	18	3	1	N	N
75	188	54	F	n/a	primary	clear-cell	N	2	uni	2.6	1	x	N	N
76	189	76	M	n/a	primary	oncocytoma	N	n/a	n/a	4	n/a	n/a	N	N
77	190	63	M	n/a	primary	papillary	N	3	uni	7.5	2	x	N	N
78	191	83	M	mut	primary	clear-cell	N	3	uni	9.6	3	x	Y	N
79	192	63	F	mut	primary	clear-cell	N	2	uni	6.8	1	0	Y	N
80	193	70	M	mut	primary	clear-cell	N	3	uni	12	2	0	N	N
81	194	56	F	mut	primary	clear-cell	N	3	uni	4.5	3	x	N	N
82	195	71	F	mut	primary	clear-cell	N	3	uni	5.3	3	x	N	N
83	196	57	F	n/a	primary	chromophobe	N	2	uni	11.5	2	0	N	N
84	197	60	M	mut	primary	clear-cell	N	3	uni	8.5	2	x	N	N
85	198	51	F	n/a	primary	clear-cell	N	2	uni	4.5	1	0	N	N
86	199	50	M	wt	primary	clear-cell	N	3	uni	13	3	0	Y	N
87	200	59	F	n/a	primary	oncocytoma	N	n/a	n/a	3.5	n/a	n/a	N	N
88	201	60	M	n/a	primary	clear-cell	N	2	multi	5.7	1	0	N	N
89	202	66	M	mut	primary	clear-cell	N	3	uni	13.3	3	0	N	N
90	203	65	F	n/a	primary	clear-cell	N	2	uni	3.5	1	x	Y	N
91	204	61	F	wt	primary	clear-cell	N	2	uni	3.5	1	x	N	N
92	205	47	F	mut	primary	clear-cell	N	3	uni	5.1	1	x	N	N
93	206	72	M	n/a	met	clear-cell	N	n/a	n/a	1.1	n/a	n/a	Y	Y
94	207	49	F	n/a	primary	angiomyolipoma	N	n/a	n/a	4.5	n/a	n/a	N	N

TG, Tumorgraft; VHL gene sequence (mut, mutation, germline and somatic; wt, wild-type); Sarc., sarcomatoid differentiation; Grade, Fuhrman nuclear grade; Size (cm); pT, pathologic T stage; pN pathologic N stage; TG-0, histologically confirmed tumor in recipient mouse cohort; TG≥2, histologically confirmed tumor passaged more than twice in mice; n/a, not applicable or assessed; uni, unifocal; multi, multifocal; Bold, tumorgraft lines giving rise to stable lines (TG≥2);

^*Tumor noted to induce hypercalcemia in tumorgraft.